Melissa L. Sokolosky

Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors

Linda S. Steelman, Patrick M. Navolanic, Melissa L. Sokolosky et al. · Oncogene · 2008 · 171 citations · Full text

Medicine, Cancer Biology, Oncology +14

Involvement of Akt-1 and mTOR in Sensitivity of Breast Cancer to Targeted Therapy

Melissa L. Sokolosky, Kristin M. Stadelman, William H. Chappell et al. · Oncotarget · 2011 · 82 citations · Full text

Medicine, Oncology, Pharmacology +17

Fusogenic-Oligoarginine Peptide-Mediated Delivery of siRNAs Targeting the CIP2A Oncogene into Oral Cancer Cells

Liliana Cantini, Christopher C. Attaway, Betsy Butler et al. · PLoS ONE · 2013 · 59 citations · Full text

Pharmacy, Molecular Pharmaceutics, Oncology +15

Inhibition of GSK-3β activity can result in drug and hormonal resistance and alter sensitivity to targeted therapy in MCF-7 breast cancer cells

Melissa L. Sokolosky, William H. Chappell, Kristin M. Stadelman et al. · Cell Cycle · 2014 · 51 citations · Full text

Medicine, Cell Biology, Oncology +17

Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapy

James A. McCubrey, Melissa L. Sokolosky, Brian D. Lehmann et al. · Advances in Enzyme Regulation · 2008 · 26 citations · Full text

Medicine, Cancer Biology, Oncology +17